On March 10, 2023 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported its participation in two upcoming conferences (Press release, Kintara Therapeutics, MAR 10, 2023, View Source [SID1234628516]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

35th Annual ROTH Conference, March 12-14, 2023 – Dana Point, CA
Mr. Robert E. Hoffman, President and CEO, will give a corporate update.
Presentation time – Monday, March 13, 2023, at 10:30 a.m. Pacific Time
4th Annual Glioblastoma Drug Development Summit, March 14-16, 2023 – Boston, MA
Dr. Dennis Brown, Chief Scientific Officer and Mr. Greg Johnson, Acting Head of Operations, will present a summary of the glioblastoma landscape and the unique attributes of Kintara’s VAL-083 program for glioblastoma.
Presentation time – Wednesday, March 15, 2023, at 4:00 p.m. Eastern Time